Originally published by our sister publication Specialty Pharmacy Continuum
By Bruce Buckley
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and patient safety controls to hawk GLP-1 weight-loss drugs outside of the legitimate prescription drug supply chain, according to a new research-based editorial in Annals of Pharmacotherapy.